Company / Working Capital
Biogen Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$5.6B
FY2025
5-year range
$1.9B / $6.5B
FY2021-FY2025
Trend
+191.7%
vs FY2024
Sector context
#9 of 215
Health Care
What the data says
Among 215 Health Care companies, Biogen is in the top 4% for working capital. Working Capital returned to growth in FY2025 after 2 years of decline, reaching $5.6B.
Based on SEC 10-K filings.
$5.6B in FY2025 with a 5-year CAGR of +12.3%. Top quartile in the Health Care sector.
Improved from $3.4B to $5.6B over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -4.8%
- 5-Year CAGR
- +12.3%
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 215This company $5.6B Sector average $957.8M
▼
+487.3% above sector average
Key checks
Key Insights
- 5-year CAGR of +12.3%, indicating consistent growth.
- In FY2025, working capital increased 191.7% year-over-year.
- Ranks #9 out of 215 companies in the Health Care sector.
- Peak working capital was recorded in FY2022.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.6B | +191.7% |
| FY2024 | $1.9B | -43.7% |
| FY2023 | $3.4B | -47.5% |
| FY2022 | $6.5B | +83.2% |
| FY2021 | $3.6B | +13.1% |
| FY2020 | $3.1B | -10.6% |
| FY2019 | $3.5B | -19.0% |
| FY2018 | $4.3B | -3.5% |
| FY2017 | $4.5B | -15.2% |
| FY2016 | $5.3B | +28.9% |
As of FY2025 · SEC 10-K · Updated Mar 3, 2026